​

1. Oncoquest™-L:

• Description: Aggregon® with a recombinant human IL-2 and patient’s lymphoma cell lysate and / or patient specific neo-antigens in a synthetic multilamellar unit structure.

• Stage: Phase II clinical trial ready

• Clinical indication: Previously untreated Stage III or IV asymptomatic, non-bulky follicular lymphoma;

• Principal Investigator TBD (to be determined)

• Status: Active, not recruiting patients

 

2. Oncoquest™-CLL:

• Description: Aggregon® with a recombinant human IL-2 and patient’s leukemic cell lysate in a synthetic multilamellar unit structure.

• Stage: Phase Ib clinical trial

• Clinical indication: Treatment-naïve patients with Chronic lymphocytic leukemia;

• PI: Dr. Shuo Ma, M.D., Northwestern University, Chicago; IND #: 15639

• Status: Active, not recruiting patients

 

3. Oncoquest™-Ovarian cancer:

• Description: Aggregon® with a recombinant human IL-2 and patient’s tumor cell lysate in a synthetic multilamellar unit structure.

• Pre IND submission

• Clinical indication: Patients with platinum-resistant, relapsed ovarian cancer.

• PI: To be determined (Proposed location: Cancer Treatment Centers of America, GA)